XFOR · X4 Pharmaceuticals Inc. Common Stock
View on chartInsiders & Stakes
| Paula Ragan President and CEO | ▲ Buy | Grant | 3,337,386 Shares held | 2/12/2025 | View profile |
| Mary DiBiase Chief Operating Officer | ▲ Buy | Grant | 1,140,980 Shares held | 2/12/2025 | View profile |
| Christophe Arbet-Engels Chief Medical Officer | ▲ Buy | Grant | 864,207 Shares held | 2/12/2025 | View profile |
| Adam S. Mostafa Chief Financial Officer | ▲ Buy | Grant | 850,000 Shares held | 2/12/2025 | View profile |
| Taveras Arthur Chief Scientific Officer | ▼ Sell | Open Market | 388,026 Shares held | 10/7/2024 | View profile |
| Adam R. Craig Executive Chairman | ▼ Sell | Open Market | 328,651 Shares held | 8/12/2026 | View profile |
| John Volpone President | ▼ Sell | Open Market | 265,305 Shares held | 8/12/2026 | View profile |
| David Kirske Chief Financial Officer | ▼ Sell | Open Market | 155,983 Shares held | 10/1/2026 | View profile |
| Derek M. Meisner Chief Legal Officer | ▼ Sell | Open Market | 145,155 Shares held | 8/17/2022 | View profile |
| Cadavid Diego Chief Medical Officer | ▲ Buy | Grant | 104,107 Shares held | 3/1/2022 | View profile |
| Aliski William Director | ▲ Buy | Grant | 96,667 Shares held | 6/10/2024 | View profile |
| Lawton Alison Frances Director | ▲ Buy | Grant | 96,667 Shares held | 6/10/2024 | View profile |
| Mark Baldry Chief Commercial Officer | ▲ Buy | Open Market | 25,337 Shares held | 5/16/2025 | View profile |
| Natasha Fay Thoren Chief Legal Officer | ▲ Buy | Grant | 9,462 Shares held | 5/20/2025 | View profile |
| Murray Stewart Director | ▲ Buy | Grant | 7,883 Shares held | 6/9/2025 | View profile |
| Keith Woods Chief Operating Officer | ▲ Buy | Grant | 6,000 Shares held | 6/9/2025 | View profile |
| Michael S. Wyzga Director | ▲ Buy | Grant | 5,555 Shares held | 6/9/2025 | View profile |
| David W. J. McGirr Director | ▲ Buy | Grant | 4,722 Shares held | 6/9/2025 | View profile |
| de Craecker Francoise Director | ▲ Buy | Grant | 4,722 Shares held | 6/9/2025 | View profile |
| Gary Bridger Director | ▲ Buy | Grant | 4,722 Shares held | 6/9/2025 | View profile |
Transaction History
| David Kirske | ▼ Sell | Open Market | 11,767 | $34K | 10/1/2026 |
| John Volpone | ▼ Sell | Open Market | 24,576 | $109K | 8/12/2026 |
| Adam R. Craig | ▼ Sell | Open Market | 47,436 | $211K | 8/12/2026 |
| David Kirske | ▼ Sell | Open Market | 8,543 | $36K | 6/30/2026 |
| David Kirske | ▼ Sell | Open Market | 16,961 | $73K | 5/12/2026 |
| Adam R. Craig | ▲ Buy | Open Market | 86,206 | $250K | 10/23/2025 |
| John Volpone | ▲ Buy | Grant | 289,881 | $0 | 8/14/2025 |
| Adam R. Craig | ▲ Buy | Grant | 289,881 | $0 | 8/14/2025 |
| David Kirske | ▲ Buy | Grant | 193,254 | $0 | 8/14/2025 |
| Murray Stewart | ▲ Buy | Grant | 1,500 | $0 | 6/9/2025 |
| Michael S. Wyzga | ▲ Buy | Grant | 1,500 | $0 | 6/9/2025 |
| de Craecker Francoise | ▲ Buy | Grant | 1,500 | $0 | 6/9/2025 |
| Gary Bridger | ▲ Buy | Grant | 1,500 | $0 | 6/9/2025 |
| Keith Woods | ▲ Buy | Grant | 1,500 | $0 | 6/9/2025 |
| David W. J. McGirr | ▲ Buy | Grant | 1,500 | $0 | 6/9/2025 |
| Natasha Fay Thoren | ▲ Buy | Grant | 3,333 | $0 | 5/20/2025 |
| Mark Baldry | ▲ Buy | Open Market | 1,032 | $3K | 5/16/2025 |
| Christophe Arbet-Engels | ▲ Buy | Grant | 850,000 | $0 | 2/12/2025 |
| Adam S. Mostafa | ▲ Buy | Grant | 850,000 | $0 | 2/12/2025 |
| Paula Ragan | ▲ Buy | Grant | 2,250,000 | $0 | 2/12/2025 |
| Mark Baldry | ▲ Buy | Grant | 600,000 | $0 | 2/12/2025 |
| Mary DiBiase | ▲ Buy | Grant | 650,000 | $0 | 2/12/2025 |
| Paula Ragan | ▼ Sell | Open Market | 76,473 | $35K | 1/24/2025 |
| Adam S. Mostafa | ▼ Sell | Open Market | 74,773 | $34K | 1/24/2025 |
| Mark Baldry | ▼ Sell | Open Market | 29,159 | $13K | 1/24/2025 |
| Mary DiBiase | ▼ Sell | Open Market | 22,258 | $10K | 1/24/2025 |
| Christophe Arbet-Engels | ▼ Sell | Open Market | 11,624 | $5K | 1/24/2025 |
| Paula Ragan | ▲ Buy | Grant | 169,940 | $0 | 1/23/2025 |
| Adam S. Mostafa | ▲ Buy | Grant | 74,773 | $0 | 1/23/2025 |
| Mark Baldry | ▲ Buy | Grant | 74,773 | $0 | 1/23/2025 |
| Mary DiBiase | ▲ Buy | Grant | 61,178 | $0 | 1/23/2025 |
| Christophe Arbet-Engels | ▲ Buy | Grant | 25,831 | $0 | 1/23/2025 |
| Mark Baldry | ▲ Buy | Open Market | 13,404 | $5K | 11/15/2024 |
| Paula Ragan | ▼ Sell | Open Market | 31,897 | $13K | 11/15/2024 |
| Paula Ragan | ▼ Sell | Open Market | 31,897 | $18K | 10/15/2024 |
| Mary DiBiase | ▼ Sell | Open Market | 67,695 | $38K | 10/7/2024 |
| Paula Ragan | ▼ Sell | Open Market | 239,436 | $132K | 10/7/2024 |
| Adam S. Mostafa | ▼ Sell | Open Market | 230,645 | $127K | 10/7/2024 |
| Mark Baldry | ▼ Sell | Open Market | 11,127 | $7K | 10/7/2024 |
| Taveras Arthur | ▼ Sell | Open Market | 76,920 | $43K | 10/7/2024 |
| Mary DiBiase | ▲ Buy | Grant | 230,645 | $0 | 10/4/2024 |
| Adam S. Mostafa | ▲ Buy | Grant | 230,645 | $0 | 10/4/2024 |
| Mark Baldry | ▲ Buy | Grant | 34,946 | $0 | 10/4/2024 |
| Paula Ragan | ▲ Buy | Grant | 532,081 | $0 | 10/4/2024 |
| Taveras Arthur | ▲ Buy | Grant | 230,645 | $0 | 10/4/2024 |
| Mary DiBiase | ▼ Sell | Open Market | 2,642 | $2K | 9/9/2024 |
| Aliski William | ▲ Buy | Grant | 45,000 | $0 | 6/10/2024 |
| de Craecker Francoise | ▲ Buy | Grant | 45,000 | $0 | 6/10/2024 |
| Murray Stewart | ▲ Buy | Grant | 45,000 | $0 | 6/10/2024 |
| David W. J. McGirr | ▲ Buy | Grant | 45,000 | $0 | 6/10/2024 |
| Gary Bridger | ▲ Buy | Grant | 45,000 | $0 | 6/10/2024 |
| Keith Woods | ▲ Buy | Grant | 45,000 | $0 | 6/10/2024 |
| Lawton Alison Frances | ▲ Buy | Grant | 45,000 | $0 | 6/10/2024 |
| Michael S. Wyzga | ▲ Buy | Grant | 45,000 | $0 | 6/10/2024 |
| Mark Baldry | ▲ Buy | Open Market | 21,646 | $15K | 5/17/2024 |
| Taveras Arthur | ▼ Sell | Open Market | 14,235 | $13K | 3/11/2024 |
| Paula Ragan | ▼ Sell | Open Market | 49,678 | $44K | 3/11/2024 |
| Adam S. Mostafa | ▼ Sell | Open Market | 52,500 | $46K | 3/11/2024 |
| Mary DiBiase | ▼ Sell | Open Market | 15,409 | $14K | 3/11/2024 |
| Mary DiBiase | ▼ Sell | Open Market | 3,683 | $4K | 2/12/2024 |
| Taveras Arthur | ▼ Sell | Open Market | 787 | $793 | 2/12/2024 |
| Paula Ragan | ▼ Sell | Open Market | 21,695 | $22K | 2/12/2024 |
| Adam S. Mostafa | ▼ Sell | Open Market | 27,721 | $28K | 2/12/2024 |
| Paula Ragan | ▼ Sell | Open Market | 39,906 | $36K | 11/3/2023 |
| Paula Ragan | ▼ Sell | Open Market | 199,531 | $146K | 11/1/2023 |
| Adam S. Mostafa | ▼ Sell | Open Market | 230,645 | $168K | 11/1/2023 |
| Mark Baldry | ▼ Sell | Open Market | 10,257 | $7K | 11/1/2023 |
| Mary DiBiase | ▼ Sell | Open Market | 67,695 | $49K | 11/1/2023 |
| Taveras Arthur | ▼ Sell | Open Market | 67,695 | $49K | 11/1/2023 |
| Adam S. Mostafa | ▲ Buy | Grant | 230,645 | $0 | 10/31/2023 |
| Paula Ragan | ▲ Buy | Grant | 532,081 | $0 | 10/31/2023 |
| Mary DiBiase | ▲ Buy | Grant | 230,645 | $0 | 10/31/2023 |
| Taveras Arthur | ▲ Buy | Grant | 230,645 | $0 | 10/31/2023 |
| Mark Baldry | ▲ Buy | Grant | 34,947 | $0 | 10/31/2023 |
| Keith Woods | ▲ Buy | Grant | 90,000 | $0 | 10/16/2023 |
| Mary DiBiase | ▼ Sell | Open Market | 2,642 | $3K | 9/8/2023 |
| Michael S. Wyzga | ▲ Buy | Open Market | 25,000 | $30K | 8/18/2023 |
| Murray Stewart | ▼ Sell | Open Market | 130,056 | $138K | 8/10/2023 |
| Murray Stewart | ▲ Buy | Grant | 269,893 | $0 | 8/9/2023 |
| Mary DiBiase | ▼ Sell | Open Market | 464 | $877 | 6/30/2023 |
| Adam S. Mostafa | ▼ Sell | Open Market | 2,641 | $5K | 6/30/2023 |
| Mary DiBiase | ▼ Sell | Open Market | 857 | $2K | 6/23/2023 |
| Adam S. Mostafa | ▼ Sell | Open Market | 5,417 | $10K | 6/23/2023 |
| Paula Ragan | ▼ Sell | Open Market | 6,724 | $13K | 6/23/2023 |
| Paula Ragan | ▼ Sell | Open Market | 6,724 | $15K | 6/15/2023 |
| Adam S. Mostafa | ▼ Sell | Open Market | 5,417 | $12K | 6/15/2023 |
| Mary DiBiase | ▼ Sell | Open Market | 857 | $2K | 6/15/2023 |
| Gary Bridger | ▲ Buy | Grant | 45,000 | $0 | 6/13/2023 |
| David W. J. McGirr | ▲ Buy | Grant | 45,000 | $0 | 6/13/2023 |
| Michael S. Wyzga | ▲ Buy | Grant | 45,000 | $0 | 6/13/2023 |
| de Craecker Francoise | ▲ Buy | Grant | 45,000 | $0 | 6/13/2023 |
| Lawton Alison Frances | ▲ Buy | Grant | 45,000 | $0 | 6/13/2023 |
| Aliski William | ▲ Buy | Grant | 45,000 | $0 | 6/13/2023 |
| Paula Ragan | ▼ Sell | Open Market | 6,292 | $12K | 5/31/2023 |
| Mary DiBiase | ▼ Sell | Open Market | 18,192 | $15K | 3/10/2023 |
| Adam S. Mostafa | ▼ Sell | Open Market | 52,500 | $44K | 3/10/2023 |
| Taveras Arthur | ▼ Sell | Open Market | 16,806 | $14K | 3/10/2023 |
| Paula Ragan | ▼ Sell | Open Market | 49,678 | $42K | 3/10/2023 |
| Taveras Arthur | ▼ Sell | Open Market | 928 | $863 | 2/13/2023 |
| Mary DiBiase | ▼ Sell | Open Market | 4,348 | $4K | 2/13/2023 |
| Adam S. Mostafa | ▼ Sell | Open Market | 27,721 | $26K | 2/13/2023 |
| Paula Ragan | ▼ Sell | Open Market | 21,695 | $20K | 2/13/2023 |
| Paula Ragan | ▼ Sell | Open Market | 13,448 | — | 8/17/2022 |
| Mary DiBiase | ▼ Sell | Open Market | 1,713 | — | 8/17/2022 |
| Derek M. Meisner | ▼ Sell | Open Market | 8,334 | — | 8/17/2022 |
| Adam S. Mostafa | ▼ Sell | Open Market | 10,834 | — | 8/17/2022 |
| Adam S. Mostafa | ▼ Sell | Open Market | 2,641 | — | 6/30/2022 |
| Mary DiBiase | ▼ Sell | Open Market | 1,578 | — | 6/30/2022 |
| Adam S. Mostafa | ▼ Sell | Open Market | 5,416 | — | 6/24/2022 |
| Mary DiBiase | ▼ Sell | Open Market | 856 | — | 6/24/2022 |
| Paula Ragan | ▼ Sell | Open Market | 6,724 | — | 6/24/2022 |
| Derek M. Meisner | ▼ Sell | Open Market | 4,166 | — | 6/24/2022 |
| Mary DiBiase | ▼ Sell | Open Market | 856 | — | 6/16/2022 |
| Paula Ragan | ▼ Sell | Open Market | 6,724 | — | 6/16/2022 |
| Adam S. Mostafa | ▼ Sell | Open Market | 5,416 | — | 6/16/2022 |
| Derek M. Meisner | ▼ Sell | Open Market | 4,166 | — | 6/16/2022 |
| Gary Bridger | ▲ Buy | Grant | 6,667 | $0 | 6/6/2022 |
| Lawton Alison Frances | ▲ Buy | Grant | 6,667 | $0 | 6/6/2022 |
| Michael S. Wyzga | ▲ Buy | Grant | 6,667 | $0 | 6/6/2022 |
| de Craecker Francoise | ▲ Buy | Grant | 6,667 | $0 | 6/6/2022 |
| Murray Stewart | ▲ Buy | Grant | 6,667 | $0 | 6/6/2022 |
| Aliski William | ▲ Buy | Grant | 6,667 | $0 | 6/6/2022 |
| David W. J. McGirr | ▲ Buy | Grant | 6,667 | $0 | 6/6/2022 |
| Paula Ragan | ▼ Sell | Open Market | 6,292 | $8K | 6/3/2022 |
| Derek M. Meisner | ▲ Buy | Grant | 105,000 | $0 | 3/1/2022 |
| Mary DiBiase | ▲ Buy | Grant | 105,000 | $0 | 3/1/2022 |
| Paula Ragan | ▲ Buy | Grant | 220,789 | $0 | 3/1/2022 |
| Taveras Arthur | ▲ Buy | Grant | 97,000 | $0 | 3/1/2022 |
| Adam S. Mostafa | ▲ Buy | Grant | 105,000 | $0 | 3/1/2022 |
| Cadavid Diego | ▲ Buy | Grant | 97,000 | $0 | 3/1/2022 |
| Mary DiBiase | ▼ Sell | Open Market | 12,545 | — | 2/11/2022 |
| Taveras Arthur | ▼ Sell | Tax Withholding | 928 | $0 | 2/11/2022 |
| Derek M. Meisner | ▼ Sell | Open Market | 15,909 | — | 2/11/2022 |
| Adam S. Mostafa | ▼ Sell | Open Market | 27,721 | — | 2/11/2022 |
| Paula Ragan | ▼ Sell | Open Market | 21,695 | — | 2/11/2022 |
| Cadavid Diego | ▼ Sell | Open Market | 928 | — | 2/11/2022 |
| Mary DiBiase | ▲ Buy | Grant | 27,000 | $0 | 9/8/2021 |
| Adam S. Mostafa | ▼ Sell | Open Market | 10,832 | $55K | 8/17/2021 |
| Derek M. Meisner | ▼ Sell | Open Market | 8,332 | $42K | 8/17/2021 |
| Paula Ragan | ▼ Sell | Open Market | 13,448 | $69K | 8/17/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
X4 Pharmaceuticals (XFOR) Faces 25% Drop, Possible Turnaround
X4 Pharmaceuticals has fallen 25.4% in the past month, but a Yahoo article highlights factors that could spark a rebound. Analysts point to recent revenue growth and a volume spike that suggest increased demand. With an RSI of 27.1 and support at $4.00, the stock may be primed for a move back toward its 52‑week range.
X4 Pharmaceuticals (XFOR) Faces 25% Drop, Possible Turnaround. X4 Pharmaceuticals has fallen 25.4% in the past month, but a Yahoo article highlights factors that could spark a rebound. Analysts point to recent revenue growth and a volume spike that suggest increased demand. With an RSI of 27.1 and support at $4.00, the stock may be primed for a move back toward its 52‑week range.